The FDA granted priority review to veligrotug for the treatment of thyroid eye disease, according to a press release from Viridian Therapeutics.
Veligrotug, an anti-insulin-like growth factor-1 receptor antibody delivered intravenously, was assigned a Prescription Drug User Fee Act date of June 30, 2026, with priority review shortening the biologics license application target review timeline from 10 months to 6 months. The BLA was supported by positive data from the phase 3 THRIVE and THRIVE2 clinical trials, which met all primary and secondary endpoints.
According to the release, veligrotug